Gemcitabine and Capecitabine for Heavily Pre-treated Metastatic Colorectal Cancer Patients - A Phase II and Translational Research Study

Anticancer Research

Volumn 34, Issue 2, 2014, Pages 845-850

  Spindler, Karen Lise G ^a,b   Pallisgaard, Niels ^a   Andersen, Rikke F ^a   Ploen, John ^a   Jakobsen, Anders ^a  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Cell free DNA; GemCap; Metastatic colorectal cancer; Plasma

Indexed keywords

ANGIOGENESIS INHIBITOR; CAPECITABINE; CYTOTOXIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; GEMCITABINE; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; GEMCAP;

ADULT; AGED; ALLELE; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER FATIGUE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CELL FREE SYSTEM; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ARTICLE; CONJUNCTIVITIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FEMALE; FUNCTIONAL STATUS; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; ISCHEMIA; MALE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SINGLE BLIND PROCEDURE; STOMATITIS; THORAX PAIN; TRANSLATIONAL RESEARCH; TREATMENT RESPONSE; BLOOD; CELL-FREE DNA; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PLASMA;

CELL-FREE DNA; GEMCAP; METASTATIC COLORECTAL CANCER; PLASMA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84897097077     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Tol J and Punt CJ: Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review. Clin Ther 437-453, 2010.
2. Chong G abstract JCO 2006, 24 (18S) 13558).
3. Plunkett W, Huang P, Searcy CE et al: Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol 3-15. 1996.
4. Tesei A, Ricotti L, De Paola F et al: In vitro schedule-dependent interactions between the multi-targeted anti-folate LY231514 and gemcitabine in human colon adenocarcinoma cell lines. Clin Cancer Res 8: 233-239, 2002.
5. Merl M, Hoimes C, Pham T et al: Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? Expert Opin Investig Drugs 18: 257-1264, 2009.
6. Spindler KL, Pallisgaard N, Vogelius I et al: Quantitative Cell Free DNA, KRAS and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. Clin Cancer Res 18: 1177-1185, 2012.
7. Spindler KL, Sorensen M, Pallisgaard N et al: Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma. Acta Oncol, 2013.
8. Spindler KL, Pallisgaard N, Andersen RF et al: Pemetrexed and gemcitabine, for chemotherapy refractory colorectal cancer Results of a phase II and translational research study J Cancer therapy x:, 2013.
9. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10, 1989.
10. Saif MW, Kaley K, Penney R et al: The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience. Anticancer Res 31: 2971-2974, 2011.
11. Bitossi R, Sculli CM, Tampellini M et al: Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients. Anticancer Res 28: 3055-3060, 2008.
12. Ferrarotto R, Machado K, Mak MP et al: A multicentre, multinational analysis of mitomycin C in refractory metastatic colorectal cancer, Eur J Cancer 48: 820-826, 2012.
13. Fakih MG, Groman A, McMahon J et al: A randomised phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 69: 743-751, 2012.
14. Yasui H, Yoshino T, Boku N et al: Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin. Jpn J Clin Oncol 39: 315-320, 2009.
15. Larsen FO, Boisen MK, Fromm AL et al: Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.Acta Oncol 51: 231-233, 2012.
16. Grothey A, Van Cutsem E, Sobrero A et al: CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet, 2013.
17. Dawson SJ, Tsui DW, Murtaza M et al: Analysis of circulating tumour DNA to monitor metastatic breast cancer. N Engl J Med, 2013.